北京大学学报（医学版） ›› 2023, Vol. 55 ›› Issue (6): 1139-1143. doi: 10.19723/j.issn.1671-167X.2023.06.029
抗神经酰胺抗体在抗磷脂综合征中的分布及临床意义
卢情怡,艾尼扎提·哈斯木,李宇菲,李春*(
)
- 北京大学人民医院风湿免疫科, 北京 100044
情怡 卢, 艾尼扎提·哈斯木,宇菲 李,春 李*()
中图分类号:
- R593.2
| 1 |
Garcia D , Erkan D . Diagnosis and management of the antiphospholipid syndrome[J]. N Engl J Med, 2018, 378 (21): 2010- 2021.
doi: 10.1056/NEJMra1705454 |
| 2 |
Miyakis S , Lockshin MD , Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4 (2): 295- 306.
doi: 10.1111/j.1538-7836.2006.01753.x |
| 3 |
Hughes GR , Khamashta MA . Seronegative antiphospholipid syndrome[J]. Ann Rheum Dis, 2003, 62 (12): 1127.
doi: 10.1136/ard.2003.006163 |
| 4 |
Zietzer A , Düsing P , Reese L , et al. Ceramide metabolism in cardiovascular disease: A network with high therapeutic potential[J]. Arterioscler Thromb Vasc Biol, 2022, 42 (10): 1220- 1228.
doi: 10.1161/ATVBAHA.122.318048 |
| 5 |
Yuan H , Zhu B , Li C , et al. Ceramide in cerebrovascular diseases[J]. Front Cell Neurosci, 2023, 17, 1191609.
doi: 10.3389/fncel.2023.1191609 |
| 6 |
Shu H , Peng Y , Hang W , et al. Emerging roles of ceramide in cardiovascular diseases[J]. Aging Dis, 2022, 13 (1): 232- 245.
doi: 10.14336/AD.2021.0710 |
| 7 |
Alexandropoulou I , Grammatikopoulou MG , Gkouskou KK , et al. Ceramides in autoimmune rheumatic diseases: Existing evidence and therapeutic considerations for diet as an anticeramide treatment[J]. Nutrients, 2023, 15 (1): 229.
doi: 10.3390/nu15010229 |
| 8 |
Radin M , Sciascia S , Erkan D , et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort[J]. Semin Arthritis Rheum, 2019, 49 (3): 464- 468.
doi: 10.1016/j.semarthrit.2019.04.009 |
| 9 |
Yin W , Li F , Tan X , et al. Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk[J]. Am J Hypertens, 2021, 34 (11): 1209- 1216.
doi: 10.1093/ajh/hpab105 |
| 10 | 张鹏, 陈夏欢, 王昊, 等. 神经酰胺在心血管疾病预测价值中的研究进展[J]. 中国心血管杂志, 2020, 25 (2): 189- 192. |
| 11 |
Bismuth J , Lin P , Yao Q , et al. Ceramide: A common pathway for atherosclerosis?[J]. Atherosclerosis, 2008, 196 (2): 497- 504.
doi: 10.1016/j.atherosclerosis.2007.09.018 |
| 12 |
Hamada Y , Nagasaki H , Fujiya A , et al. Involvement of de novo ceramide synthesis in pro-inflammatory adipokine secretion and adipocyte-macrophage interaction[J]. J Nutr Biochem, 2014, 25 (12): 1309- 1316.
doi: 10.1016/j.jnutbio.2014.07.008 |
| 13 |
Laaksonen R , Ekroos K , Sysi-Aho M , et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J, 2016, 37 (25): 1967- 1976.
doi: 10.1093/eurheartj/ehw148 |
| 14 |
Vasile VC , Meeusen JW , Medina Inojosa JR , et al. Ceramide scores predict cardiovascular risk in the community[J]. Arterioscler Thromb Vasc Biol, 2021, 41 (4): 1558- 1569.
doi: 10.1161/ATVBAHA.120.315530 |
| 15 |
Chen WF , Lee JJ , Chang CC , et al. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets[J]. Haematologica, 2013, 98 (5): 793- 801.
doi: 10.3324/haematol.2012.072553 |
| 16 |
Pignatelli P , Ettorre E , Menichelli D , et al. Seronegative antiphospholipid syndrome: Refining the value of "non-criteria" antibodies for diagnosis and clinical management[J]. Haematologica, 2020, 105 (3): 562- 572.
doi: 10.3324/haematol.2019.221945 |
| 17 |
Zhang S , Wu Z , Zhang W , et al. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome[J]. Clin Chim Acta, 2019, 495, 205- 209.
doi: 10.1016/j.cca.2019.04.065 |
| 18 |
Lopez LR , Dier KJ , Lopez D , et al. Anti-beta 2-glycoprotein Ⅰ and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome[J]. Am J Clin Pathol, 2004, 121 (1): 142- 149.
doi: 10.1309/YVQ6PX76XMYM3J29 |
| 19 |
Castanon A , Pierre G , Willis R , et al. Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively charged phospholipids other than cardiolipin[J]. Am J Clin Pathol, 2018, 149 (5): 401- 411.
doi: 10.1093/ajcp/aqy003 |
| 20 |
Li S , Bai Y , Meng J , et al. Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients[J]. Front Immunol, 2023, 14, 1107510.
doi: 10.3389/fimmu.2023.1107510 |
| 21 |
Summers SA , Chaurasia B , Holland WL . Metabolic messengers: Ceramides[J]. Nat Metab, 2019, 1 (11): 1051- 1058.
doi: 10.1038/s42255-019-0134-8 |
| [1] | 洪丽荣,陈雨佳,江庆来,贾汝琳,李春,冯亮华. 新型血栓四项联合常规凝血指标预测抗磷脂综合征患者血栓形成的价值[J]. 北京大学学报（医学版）, 2023, 55(6): 1033-1038. |
| [2] | 侯玉珂,蔡青猛,刘香君,贠泽霖,李春,张学武. 氧化型低密度脂蛋白抗体在抗磷脂综合征中的临床意义[J]. 北京大学学报（医学版）, 2022, 54(6): 1117-1122. |
| [3] | 王玉华,张国华,张令令,罗俊丽,高兰. 系统性红斑狼疮合并自发性肾上腺出血1例[J]. 北京大学学报（医学版）, 2019, 51(6): 1178-1181. |
| [4] | 顾婕昱,陆翠,石慧,杨程德. 14例恶性抗磷脂综合征病例报道及临床分析[J]. 北京大学学报（医学版）, 2018, 50(6): 1033-1038. |
| [5] | 李记,郑莉,石连杰,徐婧,舒建龙,张学武. 可溶性内皮糖蛋白在抗磷脂综合征患者的血清水平及临床意义[J]. 北京大学学报（医学版）, 2018, 50(6): 1027-1032. |
| [6] | 郑晓娟, 邓晓莉, 刘湘源. 54例抗磷脂综合征患者的妊娠结局[J]. 北京大学学报（医学版）, 2014, 46(2): 323-328. |
| [7] | 李茹*, 周云杉*, 贾园, 栗占国. 抗磷脂综合征患者血栓事件的危险因素分析[J]. 北京大学学报（医学版）, 2012, 44(5): 788-791. |
|
||
